Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion type Assertion NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_head.
- NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_provenance.
- NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion evidence source_evidence_literature NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_provenance.
- NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion SIO_000772 21423204 NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_provenance.
- NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion wasDerivedFrom befree-2016 NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_provenance.
- NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion wasGeneratedBy ECO_0000203 NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_provenance.